Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Ironwood provides investor update for second-quarter 2010

Ironwood Pharmaceuticals, Inc. today provided an update on its business activities for the second quarter of 2010.

7 Aug 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter and six months ended June 30, 2010.

7 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.

5 Aug 2010

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain.New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid. Previous research has linked a shortage of glutamine in the gut with the seepage of toxins and bacteria through the intestinal wall, irritating nerves and creating disease symptoms.

3 Aug 2010

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.

2 Aug 2010

IBS associated with structural changes in specific brain regions

A large academic study has demonstrated structural changes in specific brain regions in female patients with irritable bowel syndrome, a condition that causes pain and discomfort in the abdomen, along with diarrhea, constipation or both

23 Jul 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Sucampo Pharmaceuticals, Inc. announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation in Japanese patients has been completed.

10 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS). The trial, referred to as ASMP3001, is the first of two Phase 3 trials being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for U.S. registration. This first trial will be conducted at 120 sites in the U.S.

4 Jun 2010

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Here's another reason to breast feed your baby: Canadian researchers have discovered how a probiotic found in breast milk reduces or eliminates painful cramping in the gut. In a new research report published online in the FASEB Journal, these scientists use mice to show that a specific strain of Lactobacillus reuteri decreases the force of muscle contractions in the gut within minutes of exposure.

3 Jun 2010

Axcan extends use of Medidata Rave as EDC and CDM system

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Axcan Pharma Inc. has extended its use of Medidata Rave as its electronic data capture and clinical data management system, bringing study build and execution into the organization through Medidata training and mentoring.

2 Jun 2010

ICA hosts forum to improve quality of healthcare and lives of people with IC

The Interstitial Cystitis Association is hosting a forum and interactive webcast on Saturday, June 5, 2010 at the Hutton Hotel in Nashville. The event, "Finding Better Relief: Working with an IC Healthcare Team", gives interstitial cystitis patients the opportunity to learn about innovative treatment approaches from top IC doctors.

29 May 2010

ACG announces release of new IBD podcast series

The American College of Gastroenterology announced the release of a new podcast series, "Audio Q&A on Inflammatory Bowel Disease," featuring ACG experts answering questions on topics of most concern to IBD patients, their caregivers and loved ones. In recognition of World Digestive Health Day—2010 the Year of IBD, the College's new podcasts emphasize helping patients live well despite their IBD, and address issues surrounding reproduction and fertility; diet and nutrition; new and emerging therapies; the importance of clinical trials; and pediatric IBD.

28 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Ironwood provides investor update for second-quarter 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

Lexicon acquires equity shares of Symphony Icon Holdings

IBS associated with structural changes in specific brain regions

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Axcan extends use of Medidata Rave as EDC and CDM system

ICA hosts forum to improve quality of healthcare and lives of people with IC

ACG announces release of new IBD podcast series

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in